140 related articles for article (PubMed ID: 33010205)
1. Binding affinity determination of therapeutic antibodies to membrane protein targets: Kinetic Exclusion Assay using cellular membranes for anti-CD20 antibody.
Vaish A; Lin JS; McBride HJ; Grandsard PJ; Chen Q
Anal Biochem; 2020 Nov; 609():113974. PubMed ID: 33010205
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of the B-cell marker CD20.
Ernst JA; Li H; Kim HS; Nakamura GR; Yansura DG; Vandlen RL
Biochemistry; 2005 Nov; 44(46):15150-8. PubMed ID: 16285718
[TBL] [Abstract][Full Text] [Related]
3. A differential cell capture assay for evaluating antibody interactions with cell surface targets.
Sherman DJ; Kenanova VE; Lepin EJ; McCabe KE; Kamei K; Ohashi M; Wang S; Tseng HR; Wu AM; Behrenbruch CP
Anal Biochem; 2010 Jun; 401(2):173-81. PubMed ID: 20178770
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for recognition of CD20 by therapeutic antibody Rituximab.
Du J; Wang H; Zhong C; Peng B; Zhang M; Li B; Huo S; Guo Y; Ding J
J Biol Chem; 2007 May; 282(20):15073-80. PubMed ID: 17395584
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.
Melhus KB; Larsen RH; Stokke T; Kaalhus O; Selbo PK; Dahle J
Cancer Biother Radiopharm; 2007 Aug; 22(4):469-79. PubMed ID: 17803441
[TBL] [Abstract][Full Text] [Related]
6. A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab.
Engelberts PJ; Badoil C; Beurskens FJ; Boulay-Moine D; Grivel K; Parren PW; Moulard M
J Immunol Methods; 2013 Feb; 388(1-2):8-17. PubMed ID: 23183273
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
8. Impact of Antigen Density on Recognition by Monoclonal Antibodies.
Bar L; Dejeu J; Lartia R; Bano F; Richter RP; Coche-Guérente L; Boturyn D
Anal Chem; 2020 Apr; 92(7):5396-5403. PubMed ID: 32200619
[TBL] [Abstract][Full Text] [Related]
9. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
[TBL] [Abstract][Full Text] [Related]
10. Kinetic exclusion assay of monoclonal antibody affinity to the membrane protein Roundabout 1 displayed on baculovirus.
Kusano-Arai O; Fukuda R; Kamiya W; Iwanari H; Hamakubo T
Anal Biochem; 2016 Jul; 504():41-9. PubMed ID: 27095060
[TBL] [Abstract][Full Text] [Related]
11. Selective binding of polychlorinated biphenyl congeners by a monoclonal antibody: analysis by kinetic exclusion fluorescence immunoassay.
Chiu YW; Li QX; Karu AE
Anal Chem; 2001 Nov; 73(22):5477-84. PubMed ID: 11816577
[TBL] [Abstract][Full Text] [Related]
12. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
[TBL] [Abstract][Full Text] [Related]
13. Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance.
Erasmus MF; Dovner M; Ferrara F; D'Angelo S; Teixeira AA; Leal-Lopes C; Spector L; Hopkins E; Bradbury ARM
MAbs; 2023; 15(1):2291209. PubMed ID: 38088807
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
[TBL] [Abstract][Full Text] [Related]
15. High throughput solution-based measurement of antibody-antigen affinity and epitope binning.
Estep P; Reid F; Nauman C; Liu Y; Sun T; Sun J; Xu Y
MAbs; 2013; 5(2):270-8. PubMed ID: 23575269
[TBL] [Abstract][Full Text] [Related]
16. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
17. Development of an SPR-based binding assay for characterization of anti-CD20 antibodies to CD20 expressed on extracellular vesicles.
Wang X; Phan MM; Sun Y; Koerber JT; Ho H; Chen Y; Yang J
Anal Biochem; 2022 Jun; 646():114635. PubMed ID: 35278435
[TBL] [Abstract][Full Text] [Related]
18. The impact of different human IgG capture molecules on the kinetics analysis of antibody-antigen interaction.
Kamat V; Rafique A; Huang T; Olsen O; Olson W
Anal Biochem; 2020 Mar; 593():113580. PubMed ID: 31926892
[TBL] [Abstract][Full Text] [Related]
19. Exploring the dynamic range of the kinetic exclusion assay in characterizing antigen-antibody interactions.
Bee C; Abdiche YN; Stone DM; Collier S; Lindquist KC; Pinkerton AC; Pons J; Rajpal A
PLoS One; 2012; 7(4):e36261. PubMed ID: 22558410
[TBL] [Abstract][Full Text] [Related]
20. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
